IP Library Granted Patent US 7,879,827
Granted Patent B2
US 7,879,827 · App. 12/368,846 · Granted Feb 1, 2011

Derivatives of 4- or 5-aminosalicylic acid

Assignee: Antibe Therapeutics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,827
App. No.
12/368,846
Granted
Feb 1, 2011
Kind
B2
Abstract

The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.

Claims (17)

1. A compound of formula:

A-L-R  (I)

where:

A is

where —N═ is either at position 4 or 5,

where —NH is either at position 4 or 5,

where —NH 2 is either at position 4 or 5,

or

where —NH 2 is either at position 4 or 5;

L is either O, O—C═O, S, N or a covalent bond, to form an ester linkage, an anhydride linkage, a thioester linkage, an amide linkage or an azo linkage; and

R is a hydrogen sulfide releasing moiety selected from the group consisting of:

or a pharmacologically acceptable salt thereof.

2. The compound according to claim 1 , 4- or 5- amino-2-hydroxy-benzoic acid anhydride with N-acetyl cysteine, or a pharmacologically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmacologically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

4. The pharmaceutical composition according to claim 3 wherein the compound is 4- or 5-amino-2-hydroxy-benzoic acid anhydride with N-acetyl cysteine.

5. The compound according to claim 1 , 4-amino-2-hydroxy-benzoic acid anhydride with N-acetyl cysteine, or a pharmacologically acceptable salt thereof.

6. The compound according to claim 1 , 5-amino-2-hydroxy-benzoic acid anhydride with N-acetyl cysteine, or a pharmacologically acceptable salt thereof.

Assignments (5)
MERGER Recorded Mar 14, 2022
From: ANTIBE AMALCO INC.; ANTIBE THERAPEUTICS INC.
To: ANTIBE THERAPEUTICS INC.
Reel/Frame 059808/0216 →
ARTICLES OF CONTINUANCE & CERTIFICATE OF DISCONTINUANCE Recorded Mar 14, 2022
From: ANTIBE HOLDINGS INC.
To: ANTIBE HOLDINGS INC.
Reel/Frame 059845/0839 →
MERGER AND CHANGE OF NAME Recorded Mar 14, 2022
From: ANTIBE HOLDINGS INC.; 2831094 ONTARIO INC.; ANTIBE AMALCO INC.
To: ANTIBE AMALCO INC.
Reel/Frame 059365/0019 →
CHANGE OF NAME Recorded Nov 5, 2013
From: ANTIBE THERAPEUTICS INC.
To: ANTIBE HOLDINGS INC.
Reel/Frame 031580/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2009
From: WALLACE, JOHN L.; CIRINO, GIUSEPPE; CALIENDO, GIUSEPPE; SPARATORE, ANNA; SANTAGADA, VINCENZO; FIORUCCI, STEFANO
To: ANTIBE THERAPEUTICS INC.
Reel/Frame 022378/0888 →
Continuity (3)
Continuation 1127839500 · Mar 31, 2006
Continuation In Part 1113987100 · May 27, 2005
Related Publication 20090233886A1 · Sep 17, 2009